The use of combined hormone replacement therapy (HRT) with oestrogens and progestins in postmenopausal women has been associated with an increased risk for developing breast cancer. The reasons are not fully understood, but influence of HRT on endogenous conversion of female sex hormones may be involved. The expression of 17 beta hydroxysteroid dehydrogenases (17βHSD), which are enzymes catalysing the conversion between more or less potent oestrogens, may partly be regulated by progestins. The breast cancer cell lines T47D, MCF-7 and ZR75-1 were treated with progesterone, medroxyprogesterone acetate (MPA) or levonorgestrel for 48 and 72 hours at 10 17βHSD enzymes are important players in the regulation of sex steroids locally in breast tumours and tumoural expression of various 17βHSD-enzymes have prognostic and treatment predictive relevance. We propose a mechanism for increased breast cancer risk after HRT in which hormone replacement affects the expression of 17βHSD-enzymes, favouring the expression of reductive enzymes, which in turn could increase levels of bioactive and mitogenic estrogens in local tissue, e.g. breast tissue.
17βHSD are enzymes catalysing the conversion between oestrogens
We found that progestins affect the expression of specific 17βHSD-enzymes We propose a mechanism for increased breast cancer risk after HRT use with progestins *Highlights (for review)
Abstract
The use of combined hormone replacement therapy (HRT) with oestrogens and progestins in postmenopausal women has been associated with an increased risk for developing breast cancer. The reasons are not fully understood, but influence of HRT on endogenous conversion of female sex hormones may be involved. The expression of 17 beta hydroxysteroid dehydrogenases (17βHSD), which are enzymes catalysing the conversion between more or less potent oestrogens, may partly be regulated by progestins. The breast cancer cell lines T47D, MCF-7 and ZR75-1 were treated with progesterone, medroxyprogesterone acetate (MPA) or levonorgestrel for 48 and 72 hours at 10 17βHSD enzymes are important players in the regulation of sex steroids locally in breast tumours and tumoural expression of various 17βHSD-enzymes have prognostic and treatment predictive relevance. We propose a mechanism for increased breast cancer risk
Introduction
Hormone replacement therapy (HRT), which typically contains oestrogens or oestrogens in combination with progestin, is given to women to ease discomfort associated with reduced circulating female sex hormones at menopause. The use of HRT was greatly reduced after a report from the Women's Health Initiative which showed an increased risk of breast cancer for women receiving progestins in combination with oestradiol compared to oestradiol treatment alone [1] . This association has since been confirmed in several other studies. The breast cancer risk associated with HRT is higher for oestrogen receptor (ER)-positive cancers than for ER-negative cancers [2] [3] [4] [5] .
One in ten women will be affected by breast cancer during their life time. Several risk factors have been proposed, among them exposure to female sex hormones. The importance of oestrogens is illustrated by the fact that approximately 80% of all breast cancers express high levels of ER. Although progesterone is vital for normal growth and development of the breast, the role of this female sex hormone in the development of breast cancer, either as a single actor or as a regulator of oestrogen signalling, is under debate [6, 7] . The progesterone receptor (PgR) is an oestrogen responsive gene, and the presence of PgR is often used as a marker for functional ER signalling. Progestins are designed to mimic progesterone but with a longer half-life and better availability, however, their mechanism of action is not fully understood. It is clear that different progestins exert different effects that may be due to metabolism, dose variation, pharmacokinetics and effects mediated by steroidogenic enzymes [8] . Even though the main targets of progestins are steroid receptors, they may also bind mineralocortico receptors (MR), androgen receptors (AR) or glucocorticoid receptors (GR) [9] .
17β hydroxysteroid dehydrogenases (17βHSD), is a family of enzymes involved regulating the availability of more or less biologically potent sex hormones. 17βHSD1 efficiently catalyses the reduction of oestrone to oestradiol, whereas 17βHSD2 catalyses the oxidation of oestradiol to oestrone, testosterone to androstendione and dihydrotestosterone to 5α-androstendione. 17βHSD5 converts androstendione to testosterone and oestrone to oestradiol. We have previously shown that 17βHSD1, 17βHSD2, 17βHSD5 and 17βHSD14 are important as prognostic and treatment predictive factors in breast cancer [10] [11] [12] [13] . It has been shown that progestins influence the oestradiol and testosterone levels, and these effects have been presumed to be an effect caused by altered regulation of 17βHSD enzymes; however the contribution of separate family members of the 17βHSD-family has not been addressed [14] [15] [16] [17] [18] [19] .
Our aim was to investigate potential roles/contributions of individual 17βHSD-enzymes for the altered sex hormone conversion seen after treatment with progesterone/progestins in vitro as well as in vivo. We investigated the effect of progesterone or progestins Results were visualised using LAS1000 CCD-camera detection system (FujiFilm, Tokyo, Japan).
Semi-quanitative Real time-PCR
RNA was extracted 48 and 72 hours after treatment using SV Total RNA Isolation System (Promega, Madison, WI). The RNA was stored at -70°C. Synthesis of cDNA from total RNA was performed using the 1 st strand cDNA Synthesis kit with random hexameres (Roche Diagnostics Corporation, Indianapolis, IN, USA). mRNA expression of 17βHSD1 and 17βHSD2 was analysed according to Gunnarsson et al. [11] and 17βHSD5 according to
Jansson et al [13] . β-actin was used as endogenous reference gene and the assay was purchased from Applied Biosystems (Warrington, UK). Standard curves for all analysed genes were run on each plate, using serially diluted cDNA to normalise the runs. The obtained data from β-actin was used to normalise the sample variation in the amount of input cDNA. All samples were run as triplicates and in all experiments samples without template were used as control. The relative quantification of 17βHSD1, 17βHSD2, and 17βHSD5 were performed according to the manufacturer's description (Protocol P/N 4303859, Pearkin Elmer). (Fig. 3) .
Statistical evaluation

Mifepristone inhibits the induction of 17βHSD1 and 17βHSD5 in T47D
To investigate if the changed expression levels detected were mediated by the progesterone receptor, T47D cells were treated with mifprestone, vehicle, progesterone and mifprestone, levonorgestrel and mifprestone or MPA and mifprestone for 48 h. No changes in expression levels of 17βHSD1, 17βHSD2 or 17βHSD5 were detected when the different treatments were compared (P>0.05).
Discussion
Women receiving HRT run an increased risk of developing breast cancer when progestins are combined with oestradiol [1] [2] [3] [4] [5] . 17βHSD-enzymes have been found to play important roles in the development of breast cancer, possibly through their impact on the fine tuning of sex steroid levels. Progestins have been shown to induce conversion of oestrone to oestrasiol and vice versa in breast cancer cell lines, and this alteration in sex steroid conversion has been assumed to be a regulatory effect of 17βHSD-enzymes caused by progestins [14] [15] [16] [17] [18] [19] .
To study the effect of progesterone and progestins on the expression of 17βHSD-enzymes, we used progesterone and the most commonly used progestin in Europe and the US which are levenorgestrel and MPA respectively. The pysiological concentration detected in serum ranges from 0.1-10 nM in women using HRT [8, 20, 21] . We treated the cells with two different concentrations of progesterone/progestins reflecting the serum levels detected after HRT use. We could show that progesterone and progestins in deed does affect the levels of individual 17βHSD-enzymes in breast cancer cell lines, but that the degree to which individual 17βHSD-enzymes were affected and by which progesterone/progestin, varied to some extent. The expression level of PgR and ER varied in the cell lines, with the highest expression of PgR in T47D, intermediate in MCF7 and low in ZR75-1, this is in agreement with previous findings. [22] . The effect was most apparent in T47D which has a high PgR expression. In this cell line, treatment with levonorgestrel and progesterone led to the upregulation of reductive 17βHSD-enzymes 17βHSD1 and 17βHSD5 whereas the oxidative 17βHSD2 was down-regulated. MPA did not affect 17βHSD1-expression in this cell line, although 17βHSD5 was upregulated. The absence of effects when co-treating T47D-cells with progestins and the PgR-inhibitor mifprestone indicates that the regulation of 17βHSD-enzymes in this cell line is mediated via activation of PgR. This is in agreement with previous results showing that mifprestone blocks progestin induced steroid conversion in T47D cells [18] . Alterations were also seen in MCF7 and ZR75-1 with lower PgR expression. Adams et al [14] showed progestin induced changes in both reductive (oestrone to oestradiol) and oxidative (oestradiol to oestrone) activity in MCF-7. An increase in oestrone to oestradiol conversion could, at least partly, be explained by increases in 17βHSD1 and 17βHSD5 gene expression seen after progesterone and MPA treatment of MCF7, although, no changes were seen in 17βHSD2-expression which could explain the altered oestradiol to oestrone conversion. Couture et al [16] reported MPA induced changes in both oxidative and reductive activity in ZR75-1 cells, and furthermore, that the MPA-induced changes were inhibited by an anti-androgen, suggesting involvement of male sex hormones. In our hands, levonogestrel, but not MPA, increased the expression of 17βHSD5, which converts androstenedione into more potent testosterone, in ZR75-1, whereas MPA failed to induce this change. Although PgR seems to be important for the effects mediated by progestins, at least in a cell line harbouring high expression levels of the receptor such as T47D, there is a possibility that other steroid receptors could be involved when PgR is low or absent, and this may in part explain why the different cell lines respond differently to progesterone and different progestins. In addition to PgR, progestins have been reported to bind to GR, AR and MR, and also ER, and the extent to which these receptors are activated by different progestins may be dose dependent [23] [24] [25] [26] [27] . The failure of MPA to induce 17βHSD1-expression in T47D
could be an indication that this progestin operates on other steroid receptors, e.g. the AR.
There are studies indicating that MPA in fact inhibits the proliferation in MCF-7, ZR75-1 and T47D cells through GR and AR [28] [29] [30] .
We have investigated enzymes which have so far been attributed most relevance in breast cancer; however other 17βHSD-enzymes may also be of importance. A reason for inconsistencies between our data and previously published data on the effects of progestin stimulation on 17βHSD-activity could be generated by the relative redundancy within the 17βHSD-family, where it is unknown to what extent individual enzymes are actually involved in affecting the levels of bioactive sex steroids. Data concerning 17βHSD14, which was assessed but not presented, revealed no changes in any cell line analysed which indicates this enzyme to be of minor importance in the current setting.
Our data suggest that systemic treatment with progesterone and progestins could alter the expression levels of individual 17βHSD-enzymes, in general favouring the expression of reductive enzymes over oxidative enzymes in local tissue, e.g. breast tissue. Unopposed, this change in enzyme expression would lead to an increase in bioactive female sex steroids, e.g. oestradiol, which through its mitogenic interaction with the ER could enhance proliferation of breast epithelial cells. Schonnen et al [31] showed that levenorgestrel stimulated proliferation in MCF-7 cells through ER. It had been suggested that metabolites to progestins may bind directly to ER. In our experiments levernogestrel increased expression of 17βHSD1, decreased 17βHSD2 and increased 17βHSD5 expression, showing that progestins can indirectly influence ER activity through the regulation of steroid converting enzymes which in turn would lead to altered activity of ER.
In summary, we show that both reductive (17βHSD1 and 17βHSD5) and oxidative The results represent mean of a representative experiment ±SE,* < 0.05, ** < 0.01, *** < 0.001 
